These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 27747610)

  • 1. Intravenous Immunoglobulin (IVIg) Utilization in Immune Thrombocytopenia (ITP): A Multi-Center, Retrospective Review.
    Hsia CC; Liu Y; Eckert K; Monga N; Elia-Pacitti J; Heddle NM
    Drugs Real World Outcomes; 2015 Mar; 2(1):35-42. PubMed ID: 27747610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Appropriateness of intravenous immunoglobulin use in immune thrombocytopenia (ITP): A Canadian centre deep dive audit.
    Liu J; Pavenski K; Sholzberg M
    Transfus Apher Sci; 2019 Aug; 58(4):491-494. PubMed ID: 31105060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative net cost impact of the utilization of romiplostim and intravenous immunoglobulin for the treatment of patients with immune thrombocytopenia in Québec, Canada.
    Pettigrew M; Garces K; Deuson R; Kassis J; Laroche V
    J Med Econ; 2013; 16(2):318-26. PubMed ID: 23216012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia.
    Zeller MP; Heddle NM; Kelton JG; Hamilton K; Wang G; Sholapur N; Carruthers J; Hsia C; Blais N; Toltl L; Hamm C; Pearson MA; Arnold DM
    Transfusion; 2016 Jan; 56(1):73-9. PubMed ID: 26400824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical course and prognostic factors of childhood immune thrombocytopenia: single center experience of 10 years.
    Jung JY; O AR; Kim JK; Park M
    Korean J Pediatr; 2016 Aug; 59(8):335-40. PubMed ID: 27610182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idiopathic thrombocytopenia purpura: Treatment patterns and an analysis of cost associated with intravenous immunoglobulin and anti-D therapy.
    Simpson KN; Coughlin CM; Eron J; Bussel JB
    Semin Hematol; 1998 Jan; 35(1 Suppl 1):58-64. PubMed ID: 9523750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in IVIG use at a tertiary care Canadian center and impact of provincial use mitigation strategies: 10-year retrospective study with interrupted time series analysis.
    Murphy MSQ; Tinmouth A; Goldman M; Chassé M; Colas JA; Saidenberg E; Shehata N; Fergusson D; Forster AJ; Wilson K
    Transfusion; 2019 Jun; 59(6):1988-1996. PubMed ID: 30916409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different dosages of intravenous immunoglobulin (IVIg) in treating immune thrombocytopenia with long-term follow-up of three years: Results of a prospective study including 167 cases.
    Zhou Z; Qiao Z; Li H; Luo N; Zhang X; Xue F; Yang R
    Autoimmunity; 2016; 49(1):50-7. PubMed ID: 26525513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs of managing severe immune thrombocytopenia in adults: a retrospective analysis.
    Khellaf M; Le Moine JG; Poitrinal P; Francesconi C; Haddad A; Bierling P; Michel M; Eckert L; Launois R; Godeau B
    Ann Hematol; 2011 Apr; 90(4):441-6. PubMed ID: 20922528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canadian cost- utility analysis of intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura.
    Blackhouse G; Xie F; Levine MA; Campbell K; Assasi N; Gaebel K; O'Reilly D; Tarride J; Goeree R
    J Popul Ther Clin Pharmacol; 2012; 19(2):e166-78. PubMed ID: 22580389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura.
    Xie F; Blackhouse G; Assasi N; Campbell K; Levin M; Bowen J; Tarride JE; Pi D; Goeree R
    Clin Ther; 2009 May; 31(5):1082-91; discussion 1066-8. PubMed ID: 19539109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial Management of Childhood Acute Immune Thrombocytopenia: Single-Center Experience of 32 Years.
    Yildiz I; Ozdemir N; Celkan T; Soylu S; Karaman S; Canbolat A; Dogru O; Erginoz E; Apak H
    Pediatr Hematol Oncol; 2015; 32(6):406-14. PubMed ID: 26154620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia.
    Spadaro G; Vultaggio A; Alberto Bosi A; Reichert D; Janssen J; Lamacchia D; Nappi L; Pecoraro A; Milito C; Ferraro A; Matucci A; Bacchiarri F; Carrai V; Hibbeler A; Speckman E; Guarnieri C; Bongiovanni S; Quinti I
    Int Immunopharmacol; 2017 Mar; 44():38-42. PubMed ID: 28073042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Audit of provincial IVIG Request Forms and efficacy documentation in four Ontario tertiary care centres.
    Shih AW; Jamula E; Diep C; Lin Y; Armali C; Heddle NM; Traore A; Doherty J; Shah N; Hillis CM
    Transfus Med; 2017 Apr; 27(2):122-131. PubMed ID: 28144996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prednisone plus IVIg compared with prednisone or IVIg for immune thrombocytopenia in pregnancy: a national retrospective cohort study.
    Zhu XL; Feng R; Huang QS; Liang MY; Jiang M; Liu H; Liu Y; Yao HX; Zhang L; Qian SX; Yang TH; Zhang JY; Shen XL; Yang LH; Hu JD; Huang RW; Jiang ZX; Wang JW; Zhang HY; Xiao Z; Zhan SY; Liu HX; Wang XL; Chang YJ; Wang Y; Kong Y; Xu LP; Liu KY; Zhang XH; Yin CH; Li YY; Wang QF; Wang JL; Huang XJ; Zhang XH
    Ther Adv Hematol; 2022; 13():20406207221095226. PubMed ID: 35510211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent trends in practice patterns and comparisons between immunoglobulin and corticosteroid in pediatric immune thrombocytopenia.
    Okubo Y; Michihata N; Morisaki N; Hangai M; Matsui H; Fushimi K; Yasunaga H
    Int J Hematol; 2018 Jan; 107(1):75-82. PubMed ID: 28849369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive factors of response to IVIG in pediatric immune thrombocytopenic purpura.
    Higashide Y; Hori T; Yoto Y; Kabutoya H; Honjo S; Sakai Y; Nojima M; Yoda M; Yamamoto M; Tsutsumi H
    Pediatr Int; 2018 Apr; 60(4):357-361. PubMed ID: 29297955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and natural history of intravenous immunoglobulin-induced aseptic meningitis: a retrospective review at a single tertiary care center.
    Bharath V; Eckert K; Kang M; Chin-Yee IH; Hsia CC
    Transfusion; 2015 Nov; 55(11):2597-605. PubMed ID: 26095012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokine profiles in mouse models of experimental immune thrombocytopenia reveal a lack of inflammation and differences in response to intravenous immunoglobulin depending on the mouse strain.
    Leontyev D; Neschadim A; Branch DR
    Transfusion; 2014 Nov; 54(11):2871-9. PubMed ID: 24826802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoglobulin G dimers and immune complexes are dispensable for the therapeutic efficacy of intravenous immune globulin in murine immune thrombocytopenia.
    Tremblay T; Paré I; Bazin R
    Transfusion; 2013 Feb; 53(2):261-9. PubMed ID: 22670706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.